Form 4: Regulus Therapeutics Insider Reports Finalized Share and Option Conversions Following Novartis Acquisition

A senior executive at Regulus Therapeutics Inc. has filed a Form 4 detailing the conversion of his equity holdings into cash and contingent value rights as a result of the company's acquisition by Novartis AG.

Summary

• Christopher Ray Aker, Sr. VP & General Counsel of Regulus Therapeutics Inc. (RGLS), reported changes in his beneficial ownership of securities due to the merger with Novartis AG.
• The merger, based on an Agreement and Plan of Merger dated April 29, 2025, involved Redwood Merger Sub Inc., a wholly owned, indirect subsidiary of Novartis AG, acquiring Regulus Therapeutics Inc.
• Effective June 25, 2025, Merger Sub merged with and into Regulus Therapeutics Inc., with Regulus continuing as the surviving corporation and a wholly owned subsidiary of Novartis AG.
• Each share of Regulus common stock was tendered in exchange for $7.00 in cash (the 'Closing Amount') plus one contingent value right (CVR).
• Each CVR represents the right to receive an additional contingent payment of $7.00 in cash upon the achievement of a specified milestone.
• Performance Stock Units (PSUs) were canceled and converted into cash equal to the product of the number of underlying shares by the Closing Amount, plus one CVR per underlying share.
• 83,125 PSUs reported in this filing were unintentionally omitted from previous Form 4 filings by the Reporting Person following the achievement of performance-based vesting conditions.
• In-the-Money Stock Options (exercise price less than $7.00) were canceled and converted into cash (Closing Amount minus exercise price) plus one CVR per underlying share.
• Out-of-the-Money Stock Options (exercise price equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per underlying share, with a potential cash payment if the CVR milestone is met.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it represents a completed acquisition providing a clear exit for shareholders with an upfront cash payment and potential upside via CVRs. The primary uncertainty lies in the CVR's contingent nature, but the deal itself is a definitive event.

Positives

• The acquisition by Novartis AG provides a clear exit strategy for Regulus Therapeutics shareholders, offering a fixed cash component of $7.00 per share.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential additional upside of $7.00 per share, contingent on a specific milestone achievement, bringing the total potential value to $14.00 per share.

Negatives

• Regulus Therapeutics Inc. ceases to be an independent publicly traded company, becoming a wholly owned subsidiary of Novartis AG.
• The additional $7.00 per share from the CVR is contingent on a milestone, meaning there is no guarantee of receiving the full potential $14.00 per share.
• The unintentional omission of 83,125 PSUs from previous Form 4 filings by the Reporting Person indicates a past reporting oversight, though it is now being corrected.

Risks

• The primary risk is the contingency of the CVR payment; if the specified milestone is not achieved, shareholders will not receive the additional $7.00 per CVR.
• Out-of-the-Money Options will only receive a cash payment if the CVR milestone is achieved and the $14.00 threshold is met, otherwise no payment will be made for these options.

Future Outlook

Regulus Therapeutics Inc. is now a wholly owned subsidiary of Novartis AG. Its future operations and strategic direction will be determined by Novartis. The future financial outcome for former Regulus shareholders holding CVRs depends entirely on the achievement of the specified milestone.

Industry Context

This acquisition is consistent with a common trend in the biotechnology and pharmaceutical industries where larger companies acquire smaller, innovative firms to expand their pipeline or gain access to specific technologies. The use of Contingent Value Rights (CVRs) is a frequent mechanism in such deals, allowing acquirers to mitigate risk while providing potential upside to target company shareholders based on future clinical or regulatory achievements.

Comparison to Industry Standards

• The acquisition structure, involving an upfront cash payment combined with Contingent Value Rights (CVRs), is a common and established practice in the pharmaceutical and biotechnology sectors for deals where the acquired company's value is significantly tied to the future success of specific pipeline assets.
• Comparable transactions often include CVRs tied to clinical trial milestones (e.g., Phase 3 completion, regulatory approval) or commercialization milestones (e.g., first commercial sale, sales thresholds). While the specific milestone is not detailed in this filing, this structure aligns with industry norms for valuing early-to-mid-stage assets.
• The per-share cash consideration of $7.00 and potential total of $14.00 would be evaluated against Regulus's pre-announcement trading price, pipeline stage, and market capitalization relative to similar biotech acquisitions, though specific comparable companies or projects are not mentioned in this document.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $7.00 cash per share and one CVR per share, providing a liquidity event and potential future upside.
• Employees (including Christopher Aker): Their equity holdings (common stock, PSUs, stock options) were converted into cash and CVRs as per the merger terms.
• Company (Regulus Therapeutics Inc.): Ceased to be an independent public entity and is now a wholly owned subsidiary of Novartis AG.

Next Steps

• Achievement of the milestone specified in the CVR Agreement, which would trigger the contingent payment of $7.00 per CVR.

Key Dates

Keywords

Merger, Acquisition, SEC Form 4, Insider Transaction, Regulus Therapeutics, Novartis AG, Contingent Value Right, RGLS, Biotechnology, Pharmaceuticals